|
|
|
| Clinical study on combining Edaravone with Shuxuening Injection in treatment of patients with acute cerebral infarction |
| YANG Li |
| Chinese Medicine Internal Medicine， Changping District Hospital of Traditional Chinese Medicine, Beijing 102200, China |
|
|
|
Abstract Objective To observe the clinical efficacy of Edaravone combined with Shuxuening Injection in treatment of Acute Cerebral Infarction. Methods From January 2013 to February 2016, seventy-seven patients with acute ischemic stroke treated in Changping District Hospital of Traditional Chinese Medicine were selected, according to their visit sequences, they were randomly divided into treatment group (n=39) and control group (n=38). Patients in the control group were treated with Shuxuening Injection on the basis of regular treatment, and patients in the treatment group were treated with Edaravone combined with Shuxuening Injection. The neurologic impairment and effects after treatment were observed and compared. Results The defectiveness ratings of nervous functions, the assessment of self-care ability, and the efficacy of the treatment group were noticeably higher than those of control group, the differences were statistically significant (P < 0.05). Compared with before treatment, the plasma viscosity and total blood viscosity of the control group decreased significantly after treatment, and the difference was statistically significant (P < 0.05). There was no significant change in plasma viscosity and total blood viscosity in treatment group before and after treatment (P > 0.05). There was no adverse effect in both groups. Conclusion Shuxuening Injection combined with Edaravone has a significant clinical effect in treating acute cerebral infarction, which can effectively improve nervous function of the patients and their self-care ability.
|
|
|
|
|
|
[1] 夏彩秋,胡军荣,李鑫等,等.参附注射液联合依达拉奉治疗脑梗死效果分析[J].当代医学,2016,8（23）：142-143.
[2] 胡华，张燕辉，刘杰，等.依达拉奉联合疏血通注射液治疗急性脑梗死大鼠的疗效与安全性评价[J].中华中医药杂志，2017,32（9）：4243-4248.
[3] 中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257
[4] 王建伟，陈红芳.中国急性缺血性脑卒中诊治指南新旧版本比较[J].浙江实用医学,2016,21（3）:233-235.
[5] 成战强.舒血宁治疗急性脑梗死的临床疗效及其对患者神经功能恢复的影响[J].中医临床研究,2017,9（16）：98-99.
[6] 巫嘉陵,安中平,王世民,等.脑卒中患者日常生活活动能力量表的信度与效度研究[J].中国现代神经疾病杂志，2009,9（5）：464-468.
[7] 丁加干,张培培,黄萍,等.缺血性脑卒中发病季节与预后关系研究[J].健康教育与健康促进,2017,12（1）：42-44,75.
[8] 王勇，朱军，马春娟.依达拉奉治疗急性脑梗塞的疗效观察[J].中国现代药物应用，2016,9（17）：132-133.
[9] 谭颖.舒血宁注射液联合鼠神经生长因子治疗2型糖尿病伴脑梗死的疗效观察[J].中国实用神经疾病杂志，2016, 7（14）：22-23.
[10] 叶宪河.依达拉奉联合舒血宁治疗急性脑梗塞临床疗效观察[J].中国现代药物药物应用,2017,11（9）：78-79.
[11] 蔡松泉，蔡予.舒血宁注射液治疗急性脑梗死的疗效及其作用机制[J].吉林医学，2017,38（8）：1527-1528.
[12] 胡凯.依达拉奉联合丹参注射液治疗急性脑梗死的疗效观察[J].中国实用神经疾病杂志,2017,20（6）：15-17.
[13] 尹刘杰,李玉生,许予明.降粘抗栓片联合依达拉奉治疗脑梗死临床观察[J].中国实用神经疾病杂志，2017，20（17）：17-20.
[14] 杨瑛琳.依达拉奉治疗急性脑梗死的临床分析[J].中国现代药物应用，2016,6（12）：212-213.
[15] 刘桂玲,张薇.综合康复干预措施对急性脑卒中患者CSS评分及生活质量的影响[J].医学理论与实践，2017， 30（12）：1854-1856.
[16] 于杨，王仲坤，脱淼.影响脑梗死患者阿司匹林抵抗的随访研究[J].中风与神经疾病杂志，2017（12）：1104-1106.
[17] 臧琴波.脑梗死患者血液黏度、红细胞压积的临床观察及其相关性[J].中国医药导报，2008，5（8）：47-48
[18] 甘佳乐，徐武清，刘敬霞，等.中医药治疗脑梗死研究进展[J].吉林中医药，2016（2）：214-216.
[19] 闫海清.依达拉奉治疗脑梗死疗效观察[J].中国医药导报，2009，6（6）：160-161. |
|
|
|
